Integrated Wealth Concepts LLC Acquires 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Integrated Wealth Concepts LLC grew its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 16.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 288,101 shares of the company's stock after acquiring an additional 41,564 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Roivant Sciences were worth $3,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in Roivant Sciences by 0.3% in the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after acquiring an additional 2,404,232 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the period. Geode Capital Management LLC lifted its stake in Roivant Sciences by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock worth $91,968,000 after purchasing an additional 26,727 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Roivant Sciences in the fourth quarter worth about $52,443,000. Institutional investors own 64.76% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 21st.

Roivant Sciences Stock Down 0.1 %

Shares of NASDAQ ROIV traded down $0.02 during trading on Friday, reaching $11.57. 4,653,466 shares of the stock were exchanged, compared to its average volume of 5,886,678. The business's 50-day moving average price is $10.40 and its 200 day moving average price is $11.14. The company has a market capitalization of $8.25 billion, a price-to-earnings ratio of -77.09 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 218,041 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the transaction, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at approximately $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock valued at $14,922,538 in the last 90 days. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.